Techbio VC Dimension upsizes for $500M second fund; PE firm takes stake in Andera

Not every venture firm is going bigger with its latest fund, but techbio investor Dimension Capital has closed its latest fund at $500 million — 43% larger than its Dimension I fund, announced in early 2023. The digital biology-focused firm aims to bridge computer science and life sciences, investing in start-ups that use AI and other computational technologies to create therapeutics.

Among its investments thus far are Enveda Therapeutics Inc., whose potentially first-in-class therapy for atopic dermatitis has entered the clinic and could represent a pipeline-in-a-product opportunity; Monte Rosa Therapeutics Inc. (NASDAQ:GLUE), which has therapeutics for cancer and autoimmune diseases in human testing; and Carmot Therapeutics Inc. spinout Kimia Therapeutics Inc., seeking to build a chemical atlas that can guide therapeutic design...